Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Immunogen Inc (IMGN)

Immunogen Inc (IMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,133,671
  • Shares Outstanding, K 199,942
  • Annual Sales, $ 132,300 K
  • Annual Income, $ -44,370 K
  • 60-Month Beta 1.31
  • Price/Sales 8.36
  • Price/Cash Flow N/A
  • Price/Book 11.85
Trade IMGN with:

Options Overview

Details
  • Implied Volatility 101.39%
  • Historical Volatility 29.88%
  • IV Percentile 50%
  • IV Rank 35.08%
  • IV High 168.98% on 09/08/20
  • IV Low 64.87% on 12/18/20
  • Put/Call Vol Ratio 1.71
  • Today's Volume 591
  • Volume Avg (30-Day) 476
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 21,391
  • Open Int (30-Day) 25,313

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.18
  • Number of Estimates 7
  • High Estimate -0.15
  • Low Estimate -0.20
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.36 +5.88%
on 07/27/21
6.77 -16.25%
on 06/29/21
-1.09 (-16.12%)
since 06/28/21
3-Month
5.36 +5.88%
on 07/27/21
8.22 -31.02%
on 05/03/21
-2.35 (-29.30%)
since 04/28/21
52-Week
3.38 +67.75%
on 09/04/20
10.88 -47.89%
on 02/12/21
+1.50 (+35.97%)
since 07/28/20

Most Recent Stories

More News
Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IMGN : 5.67 (+2.53%)
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m....

IMGN : 5.67 (+2.53%)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on June 30, 2021 the compensation committee of the Company's...

IMGN : 5.67 (+2.53%)
Why Is ImmunoGen (IMGN) Down 8.7% Since Last Earnings Report?

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMGN : 5.67 (+2.53%)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on May 28, 2021 the compensation committee of the Company's...

IMGN : 5.67 (+2.53%)
Novel Anti-Cancer Drugs Permeate the Marketplace

, /PRNewswire/ -- The cancer therapeutics market is one of the largest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8 million people were diagnosed with...

SBFM : 0.1138 (+1.88%)
VSTM : 3.39 (+3.67%)
TRIL : 6.82 (+4.44%)
IMGN : 5.67 (+2.53%)
SRNE : 8.58 (+6.06%)
Interesting IMGN Put And Call Options For January 2022

Investors in ImmunoGen, Inc. saw new options become available this week, for the January 2022 expiration.

IMGN : 5.67 (+2.53%)
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna...

IMGN : 5.67 (+2.53%)
ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin(R) in Recurrent Ovarian Cancer, Regardless of Platinum Status

--Combination Demonstrates Strong Anti-Tumor Activity in Patients with High FRa Expression, with a Confirmed Overall Response Rate of 64%, Median Duration of Response of 11.8 Months and Median Progression-Free...

IMGN : 5.67 (+2.53%)
ImmunoGen (IMGN) Q1 Earnings Top, Pivotal Studies Delayed

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. Meanwhile, data readouts from pivotal studies on lead candidate get delayed due to COVID-19. Stock down.

RHHBY : 47.6400 (+0.72%)
BMY : 68.73 (+1.84%)
IMGN : 5.67 (+2.53%)
ABBV : 118.55 (+0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended...

See More

Key Turning Points

3rd Resistance Point 5.96
2nd Resistance Point 5.84
1st Resistance Point 5.76
Last Price 5.67
1st Support Level 5.56
2nd Support Level 5.44
3rd Support Level 5.36

See More

52-Week High 10.88
Fibonacci 61.8% 8.01
Fibonacci 50% 7.13
Fibonacci 38.2% 6.24
Last Price 5.67
52-Week Low 3.38

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar